Design 制药

最新新闻

• 评级变动
  Oppenheimer Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $18
  \u5e02\u573a\u8d44\u8baf · 2026/3/10
• 评级变动
  Piper Sandler Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $20
  \u5e02\u573a\u8d44\u8baf · 2026/4/29
• Craig-Hallum Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $22
  \u5e02\u573a\u8d44\u8baf · 2026/8/4
• 评级变动
  Jefferies Initiates Design Therapeutics(DSGN.US) With Buy Rating, Announces Target Price $15
  \u5e02\u573a\u8d44\u8baf · 2026/3/16
• 评级变动
  Oppenheimer Initiates Design Therapeutics(DSGN.US) With Buy Rating, Announces Target Price $18
  \u5e02\u573a\u8d44\u8baf · 2026/1/7
• 评级变动
  RBC Capital Maintains Design Therapeutics(DSGN.US) With Hold Rating, Raises Target Price to $5
  \u5e02\u573a\u8d44\u8baf · 2025/3/12
• 评级变动
  RBC Capital Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $14
  \u5e02\u573a\u8d44\u8baf · 2026/4/29
• 评级变动
  RBC Capital Initiates Design Therapeutics(DSGN.US) With Buy Rating, Announces Target Price $14
  \u5e02\u573a\u8d44\u8baf · 2026/3/10
• Craig-Hallum Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $22
  \u5e02\u573a\u8d44\u8baf · 2026/5/19
• 评级变动
  Piper Sandler Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $12
  \u5e02\u573a\u8d44\u8baf · 2025/5/9
• 评级变动
  RBC Capital Maintains Design Therapeutics(DSGN.US) With Hold Rating, Maintains Target Price $5
  \u5e02\u573a\u8d44\u8baf · 2025/8/8
• 评级变动
  Craig-Hallum Initiates Design Therapeutics(DSGN.US) With Buy Rating, Announces Target Price $15
  \u5e02\u573a\u8d44\u8baf · 2025/12/3
• RBC Capital Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $20
  \u5e02\u573a\u8d44\u8baf · 2026/5/20
• 评级变动
  Leerink Partners Upgrades Design Therapeutics(DSGN.US) to Buy Rating, Raises Target Price to $14
  \u5e02\u573a\u8d44\u8baf · 2025/12/3
• Piper Sandler Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $20
  \u5e02\u573a\u8d44\u8baf · 2026/5/27
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Design Therapeutics (DSGN) and Cartesian Therapeutics (RNAC)
  TipRanks · 2026/3/10
• 评级变动
  Craig-Hallum Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $15
  \u5e02\u573a\u8d44\u8baf · 2026/4/29
• 评级变动
  RBC Capital Upgrades Design Therapeutics(DSGN.US) to Buy Rating, Raises Target Price to $13
  \u5e02\u573a\u8d44\u8baf · 2025/11/20
• 评级变动
  Oppenheimer Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $21
  \u5e02\u573a\u8d44\u8baf · 2026/5/4
• Oppenheimer Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $21
  \u5e02\u573a\u8d44\u8baf · 2026/6/15

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。